Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the appointment of Myla Lai-Goldman, M.D., to its Board of Directors, effective September 11, 2012. Dr. Lai-Goldman has also been appointed to the Science Committee of the Company's Board of Directors.
Dr. Lai-Goldman is a managing partner at Personalized Science, LLC, and Chief Executive Officer of GeneCentric Diagnostics, Inc. and a Venture Partner with Hatteras Venture Partners. She previously served as Executive Vice President, Chief Medical Officer and Chief Scientific Officer of Laboratory Corporation of America. She is a recognized author and speaker on clinical diagnostics, including factors that lead to successful adoption of novel technologies.
"We welcome Dr. Lai-Goldman to our board, and look forward to her contributions as a renowned voice in the pathology community to add strategic counsel to our short-term and long-term growth efforts in the diagnostics market," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc.
Dr. Lai-Goldman received her undergraduate degree in biology from the University of Pennsylvania and her medical degree from Columbia University. She completed a pathology residency and surgical pathology fellowship at UCLA in Los Angeles, and followed with a hematopathology fellowship at the University of North Carolina at Chapel Hill.
"As we continue to advance our role in driving forward the clinical applications of genetic technologies, Dr. Lai-Goldman's extensive experience in clinical laboratory medicine and specifically in molecular diagnostics will be extremely insightful and contribute meaningfully to the Board's Science Committee," said Ronald M. Lindsay, Ph.D., Executive Vice President, Research and Development at Sequenom.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's expectations regarding Dr. Lai-Goldman's contributions to the Company, the Company's short-term and long-term growth efforts in the diagnostics market, and the Company's intentions and ability to continue to advance its role in driving forward the clinical applications of genetic technologies, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of the Company's technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others litigation involving the Company, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including without limitation its Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
SOURCE Sequenom, Inc.